louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01644357: Effect of a 12-month Pharmaceutical Care Program on Control of Severe Asthma
Official title: Effect of a 12-month Pharmaceutical Care Program on Severe Asthma Patient. A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Quality of Life
Lead sponsor: Federal University of Bahia
Sponsor class: OTHER
Collaborators: name: Conselho Nacional de Desenvolvimento Científico e Tecnológico
First posted: 2012-07-19
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Only a few well-designed studies have investigated the effect of pharmaceutical care on asthma patients and to date there are no published studies investigating this effect specifically on severe and refractory asthma.

The objective of this study is evaluate the effect of pharmaceutical care on asthma control and quality of life (QoL) of patients with severe or refractory asthma compared with pharmacist dispensation only.


Eligibility criteria: Inclusion Criteria:

* Patients with severe/refractory asthma presenting other respiratory disease,
* ≥ 18 years of age,
* using high dose of inhaled corticosteroids (≥ 800mcg of budesonide or equivalent)
* FEV1\<60%,
* regular visitor of the pharmacy and the physicians.

Exclusion Criteria:

* participation in other intervention study during this study,
* living in other cities,
* could not participate in all visits of the study

Primary outcomes:
measure: asthma control of symptoms
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
measure: Lung function improvement
timeFrame: 12 months
measure: Quality of life improvement
timeFrame: 12 months
Locations:
city: Salvador
country: Brazil
facility: Program for Asthma Control (ProAR) of the Federal University of Bahia
state: Bahia
Study officials:
affiliation: Federal University of Bahia
name: Pablo M Santos, Master
role: PRINCIPAL_INVESTIGATOR
affiliation: Federal University of Bahia
name: Álvaro A Cruz, Professor
role: STUDY_DIRECTOR
affiliation: Federal University of Bahia
name: Lúcia B Noblat, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02066857: Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly
Official title: Use of Cast Versus Removable Splints for Minimally Displaced Distal Radius Fractures in Elderly Patients: A Prospective, Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Radius; Fracture, Lower or Distal End
Keywords: Wrist fracture
Radius fracture
Elderly
Splint
Cast
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2014-02-20
Enrollment: 5
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this prospective randomized study is to add to the body of knowledge on the treatment of minimally displaced distal radius fractures in patients over 60 years of age. The investigators believe that treating minimally displaced distal radius fractures in people over 60 with a removable splint and early range of motion will provide greater patient satisfaction, fewer complications, and earlier functional returns to pre-injury for these patients compared to those treated with a short arm cast which immobilizes the limb for at least four weeks, and has been shown to lead to longer recovery and possible residual stiffness. The investigators hope to provide sufficient evidence in directing treatment that will give the most efficacious and the most satisfactory return of prior function to patients. Since distal radius fractures in the elderly are common because of poorer bone quality, the elderly proportion of the population is increasing, and controlling health costs is of current concern, answering the question of which treatment produces the best results for all these concerns is of increasing importance now.


Eligibility criteria: Inclusion Criteria:

1. Colles' Fracture - Distal radius fracture with dorsal angulation, apex volar (satisfies non-operative radiographic criteria before or after reduction
2. Isolated upper limb injury
3. No previous wrist fracture
4. Available for follow-up
5. Between 60 and 100 years of age

Exclusion Criteria:

1. Less than 60 years of age
2. Fractures that do not meet non-operative criteria or are deemed unstable by surgeon, subsequently requiring surgery after first clinic visit.

Primary outcomes:
measure: Change in Wrist Range of Motion (ROM)
timeFrame: Baseline, Month 3
measure: Mean Mayo Wrist Score
timeFrame: Baseline, Week 2, Week 6, Week 12
measure: Change in Grip Strength
timeFrame: Baseline, Month 3
measure: Complication Rate
timeFrame: Duration of Study (Up to 3 Months)
measure: Mean Pain Score
timeFrame: Baseline, Week 2, Week 6, Week 12
Secondary outcomes:
measure: Mean Disabilities of the Arm and Shoulder (DASH) Questionnaire Score
timeFrame: Baseline, Week 2, Week 6, Week 12
measure: Change in SF-12 QOL
timeFrame: Baseline, Month 3
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory Orthopaedics and Spine Center
state: Georgia
Study officials:
affiliation: Emory University
name: Claudius Jarrett, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05855057: Effectiveness of US-Guided PCNL Different Positions in Renal Stones Treatment
Official title: A Retrospective Single Centered Cohort Study Comparing The Effectiveness of Ultrasound-Guided PCNL Different Positions in Renal Stones Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Percutaneous Nephrolithotomy
Renal Stones
Ultrasound Therapy; Complications
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2023-05-11
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 123 patients who underwent Percutaneous nephrolithotomy at the period from 2018 to 2022 and were diagnosed with consecutive, adult obese patients (age \>18-70 years) with renal stones diameter ≥2 cm

Brief summary: The aim of this study is to compare the effectiveness of Ultrasound-Guided Percutaneous nephrolithotomyin different positions supine, prone positions and flank suspend supine position in renal stones treatment.

Detailed description: Percutaneous nephrolithotomy (PCNL) has become the choice of modality for the treatment of large and complicated renal calculi. Initially, percutaneous access to the kidney was only performed in the prone position, as described sixty years ago.

Eligibility criteria: Inclusion Criteria:

* patients who underwent Percutaneous nephrolithotomy
* Patient's age from \>18 - 70 years old.
* Body mass index (30-40 kg/m2).
* Both sex
* Renal stones diameter ≥2 cm
* Cardiac patients

Exclusion Criteria:

* Patient refusal.
* Pregnant women.
* Patients with renal anomalies.
* Transplanted kidney.
* Uncorrected coagulopathy, or active infection.

Primary outcomes:
measure: Stone clearance rate
timeFrame: 3 months postoperatively
Secondary outcomes:
measure: Operative time
timeFrame: Intraoperatively
measure: Complication rates
timeFrame: 48 hours Postoperatively
measure: Stone-free rates
timeFrame: 48 hours Postoperatively
Other outcomes:
Locations:
city: Benha
country: Egypt
facility: Benha University Hospitals
Study officials:
References:
Clinical trial NCT00405457: Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Official title: Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dry Eye
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2006-11-30
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy, safety and tolerability of a combination of Optive® Artificial Tears with Restasis®.The primary hypothesis is that the Ocular Surface Disease Index (OSDI) score and symptoms will be the same or lower than baseline after treatment in these patients. The patients will tolerate the combination of Restasis® and Optive® with a low incidence of clinical adverse events.


Eligibility criteria: Inclusion Criteria:

* · Males or females \> 18 years old

  * Patients currently taking Restasis® for at least 3 months in duration and using artificial tears as needed for dry eye.
  * Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

* · Patients using Restasis® for less than 3 months.

  * Known contraindications to any study medication or ingredients
  * Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
  * Other active uncontrolled ocular diseases or uncontrolled systemic disease

Primary outcomes:
measure: efficacy
timeFrame: 1 yr 3 months
Secondary outcomes:
measure: dry eye symptoms
timeFrame: 1 yr 3 months
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Minnesota Eye Consultants
state: Minnesota
Study officials:
affiliation: Minnesota Eye Consultants
name: David Hardten, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04731857: Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes
Official title: Diagnostic Value of Exome and Genome Sequencing As Well As Conventional Methods in Rare Diseases and Familial Tumor Syndromes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rare Diseases
Genetic Predisposition
Keywords: Rare Diseases
Genetic Predisposition
Next Generation Sequencing (NGS)
Polygenic risk scores (PRSs)
Repeat-Expansion
Genetic variation
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2021-02-01
Enrollment: 12000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with genetic diseases of any age and, if present, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen.

Brief summary: For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.

Detailed description: The methodological developments of the last few years allow the broad use of next-generation-sequencing (NGS) -based methods in the routine molecular genetic diagnosis of genetic diseases.The aim of the retrospective data analysis is to create a solid data basis for further discussion regarding the development and mapping of diagnostic algorithms and subsequent supply routes. For the genome data, this evaluation is to be expanded to include the evaluation of the Polygenic risk scores (PRSs) in the sense of an additional finding.

Eligibility criteria: Inclusion Criteria:

* Patient with genetic disease or
* Family members
* Genetic analysis between 10/2016 and 12/2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen

Exclusion Criteria:

- None

Primary outcomes:
measure: Diagnosis
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Tübingen
country: Germany
facility: University Hospital Tübingen
Study officials:
affiliation: University Hospital Tübingen
name: Tobias Haack, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06732557: Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture
Official title: Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Forward Head Posture
Keywords: forward head posture
Mulligan Mobilization
Muscle energy technique
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: sixty patients with forward head posture will be randomized to three groups Group A: will receive traditional treatment ( isometric exercise for deep neck flexors plus sub occipital release).

Group B: will receive traditional treatment plus muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid.

Group C: will receive traditional treatment plus mulligan mobilization


Eligibility criteria: Inclusion Criteria:

* Age between 18 to 45 years
* Non specific neck pain reproduced by neck movement
* Neck pain at least within the last three months
* Limitation in cervical range of motion

Exclusion Criteria:

* cervical spine surgery or injury
* neurologic deficits, infection or inflammation
* cervicogenic headache

Primary outcomes:
measure: Pain
timeFrame: Before the first session and at the end of the treatment program ( one month)
measure: Cervical range of motion
timeFrame: Before the first session and after the end of the treatment program ( one month)
measure: Disability measurement
timeFrame: Before the first session and after the end of the treatment program ( one month)
measure: Cervicovertebral angle
timeFrame: Before the first session and after the end of the treatment program ( one month)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06187857: A Virtually Delivered Memory Rehabilitation Protocol in Older Adults
Official title: A Feasibility Study of a Virtually Delivered Ecologically Oriented Neurorehabilitation of Memory (EON-MEM) Protocol in Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Memory Dysfunction
Neurorehabilitation
Lead sponsor: Brigham Young University
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 25
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A feasibility study of twenty-five older adults completing the same virtual procedures.
Primary purpose: TREATMENT

Brief summary: The investigators conducted a feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults. The primary purposes of this study included determining the feasibility of conducting EON-Mem virtually with older adults and whether a randomized control trial using EON-Mem in older adults is of value.

Detailed description: Twenty-five older adults aged 55 years and older were recruited for participation in the EON-Mem training program adapted and administered virtually. Measures of emotional functioning and cognitive functioning were administered before and following the intervention. Participants attended one virtual treatment session per week for a total of six weeks with daily homework assignments. A priori, feasibility was set at an 80% completion rate. To address questions regarding feasibility, the investigators calculated descriptive statistics on sample information.

Eligibility criteria: Inclusion Criteria:

* Individuals 55 and older

Exclusion Criteria:

* Evidence of cognitive dysfunction on the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as evidenced by a score of 3.3 or more
* History of moderate-to-severe TBI
* History of stroke
* Dementia/neurological diagnoses
* Current chemotherapy or radiation
* Current or history of brain cancer
* Poor sensory function including uncorrected vision, hearing, or speaking impairments that could interfere with learning the intervention, including nonnative English speakers.

Primary outcomes:
measure: Feasibility of study protocols.
timeFrame: Through study completion, an average of 8 weeks.
Secondary outcomes:
measure: Memory Outcomes: Repeatable Battery for Neuropsychological Status
timeFrame: Through study completion, an average of 8 weeks.
measure: Memory Outcomes: Ecological Memory Simulations
timeFrame: Through study completion, an average of 8 weeks.
Other outcomes:
Locations:
city: Provo
country: United States
facility: Brigham Young Unversity
state: Utah
Study officials:
References:
Clinical trial NCT04475757: Ultra Sounded Guided Posterior Transverse Abdominis Plane & Lateral FEMORAL Cutaneous Nerve Blocks Analgesia Post Hip Hemiarthroplasty
Official title: Effectiveness Of Ultra Sounded Guided Posterior Transverses Abdominis Plane & Lateral Femoral Cutaneous Nerve Blocks For Analgesia After Hip Hemiarthroplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Pain
Lead sponsor: Dubai Health Authority
Sponsor class: OTHER_GOV
First posted: 2020-07-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: POSTOPERATIVE PATIENT UNDERGOING HIP HEMIARTHROPLASTIC SURGERY

Brief summary: COMBINED ULTRASOUND GUIDED POSTERIOR TRANS VERSUS ABDOMINAL PLANE \& LATERAL FEMORAL CUTANEOUS NERVE BLOCKS FOR POSTOPERATIVE ANALGESIA AFTER HIP HEMIARTHROPLASTIC SURGERY

Detailed description: TO EVALUATE THE EFFECTIVENESS OF POSTOPERATIVE ANALGESIA FOR HIP HEMIARTHROPLASTIC SURGERIES BY USING ULTRASOUND GUIDED POSTERIOR TRANS VERSUS ABDOMINAL PLANE \& LATERAL FEMORAL CUTANEOUS NERVE BLOCKS

Eligibility criteria: Inclusion Criteria:

* Hemiarthroplaty surgery
* ASA 1 - ASA 4

Exclusion Criteria:

* ALLERGIC TO LOCAL ANESTHETICS
* PATIENT REFUSAL

Primary outcomes:
measure: PAIN MANAGEMENT
timeFrame: 2 DAYS
Secondary outcomes:
Other outcomes:
Locations:
city: Dubai
country: United Arab Emirates
facility: Dubai Health Authority
Study officials:
References:
Clinical trial NCT03379857: Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke
Official title: Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Stroke
Cannabis Use
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2017-12-20
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Cannabis User
Primary purpose: PREVENTION

Brief summary: Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects.

There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.


Eligibility criteria: Inclusion Criteria:

* Subject between 18 and 45 years old
* Stroke confirmed by medical imaging
* Written informed consent (subject, nearby or emergency procedure)
* Subject affiliate to a local healthcare insurance office
* For female of childbearing potential, an adequate contraceptive measur

Exclusion Criteria:

* Subject with psychiatric disorder, unable to understand the study or cooperate
* Subject under guardianship or forfeiture of liberty
* Pregnant or breastfeeding woman
* Subject in period of exclusion due to another study or still in follow-up of an interventional study

Primary outcomes:
measure: Evaluation Cannabis use
timeFrame: 12 months
measure: Reversible vasoconstriction on medical imaging of intracranial arteries at different moment
timeFrame: 12 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Besancon
country: France
facility: Chu Jean Minjoz
city: Colmar
country: France
facility: Unite Neuro-Vasculaire
city: Dijon
country: France
facility: Chu Bocage
city: Mulhouse
country: France
facility: C.H. G. Muller
city: Nancy
country: France
facility: Hopital Central
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
affiliation: Hôpitaux Universitaires de Strasbourg
name: Valérie WOLFF, MD
role: PRINCIPAL_INVESTIGATOR
References: